Premium
Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia
Author(s) -
Cole Adam R.
Publication year - 2013
Publication title -
the febs journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 204
eISSN - 1742-4658
pISSN - 1742-464X
DOI - 10.1111/febs.12407
Subject(s) - gsk 3 , schizophrenia (object oriented programming) , mood disorders , glycogen synthase , mood , neuroscience , bipolar disorder , kinase , biology , bioinformatics , psychology , psychiatry , glycogen , genetics , biochemistry , anxiety
The dominant genetic and environmental causes of mood disorders and schizophrenia have not been forthcoming, so alternative approaches are required to elucidate the mechanisms underlying these diseases and to develop improved treatments for use in the clinic. Pharmacological evidence implicates glycogen synthase kinase 3 ( GSK 3) as a key target of current therapeutics, and this is well supported by genetic studies in animal models. Several upstream regulators of GSK 3 are also genetically associated with mood disorders and schizophrenia, further suggesting convergence on GSK 3 signalling. Whereas pathways upstream of GSK 3 are being elucidated, relatively little progress has been made in identifying targets downstream of GSK 3 that mediate its functional effects. This is important, because these substrates themselves could become next‐generation therapeutic targets that are more potent and specific than current therapeutics targeting GSK 3. Here, a few likely candidates and their connection to mood disorders and schizophrenia are discussed.